Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Abiraterone Acetate in Combination With Tildrakizumab (ACTIon)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04458311
Recruitment Status : Not yet recruiting
First Posted : July 7, 2020
Last Update Posted : July 7, 2020
Sponsor:
Collaborator:
Sun Pharma Global FZE
Information provided by (Responsible Party):
Institute of Cancer Research, United Kingdom

Brief Summary:
The purpose of this study is to find out the side effects and safety of a combination of the anti-IL23 targeting monoclonal antibody tildrakizumab in combination with abiraterone acetate in men with metastatic castration resistant prostate cancer and to determine the most appropriate dose of this combination. In the Phase I part of this study small groups of patients will be treated with increasing doses of tildrakizumab in combination with a fixed dose of abiraterone acetate(1000mg once daily). Once Phase I has been completed the combination with the optimum safety and pharmacokinetic/pharmacodynamic profile will be taken forward to the Phase II part of the study. The Phase II part of the study will evaluate the optimized dose/schedule identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.

Condition or disease Intervention/treatment Phase
Metastatic Castration Resistant Prostate Cancer Drug: Abiraterone Acetate Drug: Tildrakizumab Phase 1 Phase 2

Detailed Description:

The trial will be divided into 2 parts: Phase I and Phase II. The Phase I study will adopt a Bayesian Continual Reassessment Method. Patients will receive single-agent abiraterone 1000 mg orally, once daily (continuous dosing) along with prednisolone at 5 mg BD for up to 4 weeks. Upon confirmation of PSA progression, tildrakizumab IV will be started and given once every 4-weeks in combination with the fixed dose abiraterone (and prednisolone). The starting dose of tildrakizumab will be 100mg with single dose escalations to 300mg and 600mg to determine the RP2D to take forward to the Phase II study. Depending on the number of responses observed, dose levels that are deemed tolerable may be expanded to up to a total of 10 patients who are evaluable for response

The Phase II study will employ a two-stage Minimax design, recruiting up to 25 patients. During the first stage 15 evaluable patients will be enrolled and followed for a minimum of 2 cycles each. If there are one or more responses confirmed at least 4-weeks later an additional 10 evaluable patients will be recruited. If 4 or more responses are seen in the 25 patients evaluable for response, the combination will be deemed successful, warranting further evaluation in subsequent phases of testing. In the phase II study patients will start taking 1000mg abiraterone as an oral tablet once daily along with 5mg of prednisolone twice daily on Day -28 for the first 4 weeks. Upon confirmation of PSA progression, the tildrakizumab will be given as an intravenous infusion at the dose established in the Phase I safety run in part of the study in combination with the abiraterone (and prednisolone)from Cycle 1 Day 1 onwards.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 55 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: ACTION: Phase I/II Trial of Abiraterone Acetate in Combination With Tildrakizumab (Anti-IL23 Targeting Monoclonal Antibody) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Estimated Study Start Date : October 1, 2020
Estimated Primary Completion Date : October 1, 2023
Estimated Study Completion Date : October 1, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Phase I
Increasing doses of tildrakizumab in combination with a fixed dose of abiraterone to establish the recommended phase II dose in patients with metastatic castration resistant prostate cancer..
Drug: Abiraterone Acetate
Supplied as 125 mg tablets
Other Name: Yonsa

Drug: Tildrakizumab
Tildrakizumab will be supplied in single-use 100 mg/mL glass vials intended for IV infusion.

Experimental: Phase II
The Phase II part of the study will evaluate the recommended phase II dose identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.
Drug: Abiraterone Acetate
Supplied as 125 mg tablets
Other Name: Yonsa

Drug: Tildrakizumab
Tildrakizumab will be supplied in single-use 100 mg/mL glass vials intended for IV infusion.




Primary Outcome Measures :
  1. Phase I - To describe the safety and tolerability of abiraterone acetate and tildrakizumab when given in combination. To establish a RP2D for tildrakizumab, in combination with abiraterone. [ Time Frame: 12 months ]
    To determine a maximum tolerated dose (MTD) of tildrakizumab by establishing the dose at which the DLT rate is as close to the target DLT rate of 15% as possible, in combination with abiraterone at 1000 mg OD with prednisolone at 5 mg bid, and is deemed to be tolerable by the Safety Review Committee. This will be the RP2D for tildrakizumab.

  2. Phase II - To determine the antitumour activity of tildrakizumab (at RP2D) in combination with abiraterone in men with mCRPC. [ Time Frame: 12 months ]

    Antitumour activity will be defined by response rate on the basis of the following outcomes. If any of the following occur, patients will be considered to have responded:

    • PSA decline ≥ 50% criteria confirmed 4-weeks or later and/or,
    • Confirmed soft tissue objective response by RECIST (v1.1) in patients with measurable disease and/or,
    • ONLY for patients with detectable circulating tumour cell (CTC) count of ≥ 5/7.5ml blood at baseline, conversion of CTC count to <5/7.5ml blood nadir.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up.
  2. Age 18 or above.
  3. Histologically or cytologically proven adenocarcinoma of the prostate.
  4. Metastatic castration resistant prostate cancer
  5. Documented prostate cancer progression as assessed by the investigator with RECIST (v1.1) and PCWG3 criteria with at least one of the following criteria:

    1. Progression of soft tissue/visceral disease by RECIST (v1.1) and/or,
    2. Progression of bone disease by PCWG3 bone scan criteria and/or,
    3. Progression of PSA by PCWG3 PSA criteria and/or,
    4. Clinical progression with worsening pain and need for palliative radiotherapy for bone metastases.
  6. Patients that have progressed after either enzalutamide or abiraterone treatment (having received a minimum of 12-weeks of enzalutamide or abiraterone).
  7. Ongoing androgen deprivation maintaining serum testosterone of less than 50 ng/dL (less than 2.0 nM) is mandatory.
  8. Life expectancy of at least 12-weeks.
  9. World Health Organisation (WHO) performance status of 0-2
  10. Able to swallow the study drug.
  11. Archival tissue must be available for research analysis.
  12. Patients must have disease that is amenable to biopsy and must be willing to undergo tumour biopsies.
  13. Participants must either have measurable disease according to RECIST v1.1 or if the patient has bone-only metastases, the CTC count at baseline must be ≥ 5/7.5 ml blood.
  14. Haematological and biochemical indices within the required ranges in protocol. These measurements must be performed within one week prior to the patient's first dose of any investigational medicinal products (IMP).

Exclusion Criteria:

  1. Patients with predominantly small cell or neuroendocrine differentiated prostate cancer are not eligible.
  2. Prior therapy, including major surgery, chemotherapy, radium-223, or other anti-cancer therapy within 4-weeks prior to IMP administration. The use of bisphosphonates or RANK ligand inhibitors in patients with known osteopenia or osteoporosis or bone metastases is permitted. A single fraction of palliative radiation is permitted if at least 14-days before starting trial treatment.
  3. Prior hormonal treatment exclusions as follows:

    • prior flutamide treatment during previous four-weeks N.B. Patients whose PSA did not decline in response to antiandrogens given as a second line or later intervention will only require a 14-day washout;
    • prior bicalutamide (Casodex) and nilutimide (Nilandron) treatment during previous six-weeks;
    • prior progesterone, medroxyprogesterone, progestins, cyproterone acetate, tamoxifen, and 5-alpha reductase inhibitors during previous two-weeks (14-days).
  4. Prior limited field radiotherapy within the previous two weeks (14-days), or wide field radiotherapy within the previous four weeks of trial entry.
  5. Participation in another interventional clinical trial and any concurrent treatment with any investigational drug within four weeks prior to IMP administration.
  6. Any toxicities due to prior chemotherapy and/or radiotherapy that have not resolved to NCI-CTCAE v5.0 Grade ≤1 with the exception of chemotherapy induced alopecia and Grade 2 peripheral neuropathy.
  7. Clinical evidence of hyperaldosteronism or hypopituitarism.
  8. Use of drugs that are known strong CYP3A4 inducers and CYP2D6 substrates with a narrow therapeutic index (please refer to http://medicine.iupui.edu/clinpharm/ddis/table.aspx). Seville orange or grapefruit products, and any herbal medications should be avoided for four weeks prior to starting trial treatment.
  9. Malabsorption syndrome or other condition that would interfere with enteral absorption of the study drugs.
  10. Known intracerebral metastases
  11. Any of the following cardiac criteria:

    1. QT interval > 470 msec.
    2. Clinically important abnormalities including rhythm, conduction or ECG changes (left bundle branch block, third degree heart block).
    3. Factors predisposing to QT prolongation including congenital long QT syndrome; family history of prolonged QT syndrome, unexplained sudden death (under 40); concomitant medications known to prolong QT interval.
    4. Coronary artery bypass, angioplasty, vascular stent, myocardial infarction, angina or congestive heart failure (NYHA ≥ grade 2) in the last 6 months (see appendix 5 for NYHA scale).
  12. Uncontrolled hypotension (systolic blood pressure < 90mmHg and or diastolic blood pressure < 50 mmHg).
  13. Uncontrolled hypertension on optimal medication (systolic blood pressure >180, diastolic blood pressure > 100).
  14. Patients with known history of adrenal insufficiency or mineralocorticoid excess.
  15. Patients with a significant history of liver disease (Child-Pugh B or C, viral or other hepatitis, current alcohol abuse or cirrhosis).
  16. Known history of hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
  17. At high medical risk because of non-malignant systemic disease including active infection.
  18. Known history of tuberculosis.
  19. Poorly controlled diabetes with HbA1C > 7.5%.
  20. Malignancy other than prostate cancer within three-years of trial entry with the exception of adequately treated basal cell carcinoma. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy must have no evidence of that disease for at least-three years and be deemed at negligible risk for recurrence, are deemed eligible.
  21. Immunocompromised patients including patients who have previously received organ transplants or are on long-term immunosuppression (e.g. corticosteroids of > 10 mg daily equivalent of prednisolone).
  22. Active or uncontrolled autoimmune disease requiring corticosteroid therapy or other forms of systemic immunosuppression.
  23. Any other finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect interpretation of the results or renders the patients at high risk from treatment complications e.g. patients with a hypersensitivity to tildrakizumab, abiraterone or prednisolone.
  24. Patients with female partners of child-bearing potential (unless they agree to take measures not to father children by using a barrier method of contraception [condom plus spermicide] or to sexual abstinence effective from the first administration of any of the study drugs throughout the trial and for six months afterwards. Men with partners of child-bearing potential must also be willing to ensure that their partner uses an effective method of contraception for the same duration for example, hormonal contraception, intrauterine device, diaphragm with spermicidal gel or sexual abstinence). Men with pregnant or lactating partners must be advised to use barrier method contraception (for example, condom plus spermicidal gel) to prevent exposure of the foetus or neonate.

    NB. Abstinence is only considered to be an acceptable method of contraception when this is in line with the preferred and usual lifestyle of the participants. Periodic abstinence (e.g., calendar, ovulation, sympathothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception

  25. Prior bone marrow transplant.
  26. Extensive radiotherapy to greater than 25% of bone marrow within 8 weeks.
  27. Any other condition, which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.
  28. Symptoms of COVID-19 and/or documented COVID-19 infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04458311


Contacts
Layout table for location contacts
Contact: Ruth Matthews, PhD 0208 722 4048 ruth.matthews@icr.ac.uk
Contact: Alison Turner, PhD 0208 722 4303 alison.turner@icr.ac.uk

Locations
Layout table for location information
Switzerland
Bellinzona Hospital
Bellinzona, Switzerland
United Kingdom
Cancer Research Centre at Weston Park Hospital
Sheffield, England, United Kingdom, S1O 2SJ
Belfast City Hospital
Belfast, UK, United Kingdom
The Royal Marsden Hospital Foundation Trust
Sutton, UK, United Kingdom
Contact: Johann S De Bono, MD         
Addenbrooke's Hospital
Cambridge, United Kingdom
Freeman Hospital
Newcastle upon Tyne, United Kingdom
University Hospitals Southampton NHS Foundation Trust
Southampton, United Kingdom
Sponsors and Collaborators
Institute of Cancer Research, United Kingdom
Sun Pharma Global FZE
Investigators
Layout table for investigator information
Study Director: Johann De Bono, MD National Health Service, United Kingdom
Layout table for additonal information
Responsible Party: Institute of Cancer Research, United Kingdom
ClinicalTrials.gov Identifier: NCT04458311    
Other Study ID Numbers: CCR5163
First Posted: July 7, 2020    Key Record Dates
Last Update Posted: July 7, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases
Abiraterone Acetate
Antineoplastic Agents
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 Enzyme Inhibitors